-
E-mail us
E-mail us
· TESARO''s marketed product portfolio consist of a single product, Zejula. It is a PARP inhibitor which is approved as maintenance treatment for ovarian cancer irrespective of BRCA mutation.
Read More· The FDA approved Tesaro''s once-daily, oral poly(ADP ribose) polymerase (PARP) inhibitor Zejula (niraparib) for the maintenance treatment of women with recurrent epithelial ovarian, fallopian ...
Read MoreIn 2017, Tesaro''s Zejula (niraparib) achieved a third PARP inhibitor approval while breaking ground as maintenance therapy for platinum-sensitive ovarian cancer regardless of BRCAm status. GlobalData believes that PARP inhibitor developers will be rewarded by taking broader aim at disease spaces outside of BRCA m ovarian and breast cancers, including gastric, …
Read MoreTESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.
Read MoreZejula (niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer. Discovered and developed by US biopharmaceutical company Tesaro, Zejula received marketing approval from the US Food and Drug Administration (FDA) as a maintenance treatment for women with ...
Read MoreTESARO, Inc. has developed the approved product Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor indicated for ovarian cancer. The acquisition is expected to increase the application of Zejula for multiple cancer treatments.
Read More· GSK/Tesaro PARP in hibitor Ze ju la wins an oth er speedy re view mHealth innovation: Identifying the best patient-centered technology for clinical trials
Read MoreGSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer, following an agreement reached with Takeda Australia. This transfer of marketing authorisation is an important first step in the process for GSK to make this medicine
Read More· In 2017 Zejula was the first PARP inhibitor approved as second-line maintenance treatment of ovarian cancer regardless of BRCA mutations, leading to speculation that the drug had unique potential to reach a broader range of patients. "However, since then
Read MoreFacts of Zejula (niraparib) capsules Product: ZEJULA (niraparib) capsules, for oral use Initial U.S. Approval: 2017 Capsules: 100 mg Company: TESARO Indication: epithelial ovarian, fallopian tube, or primary peritoneal cancer South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, "Zejula (niraparib)" to all locations in …
Read More· In 2017, Tesaro''s Zejula (niraparib) achieved a third PARP inhibitor approval while breaking ground as maintenance therapy for platinum-sensitive ovarian cancer regardless of BRCAm status. GlobalData believes that PARP inhibitor developers will be rewarded by taking broader aim at disease spaces outside of BRCA m ovarian and breast cancers, including …
Read MoreWALTHAM, MA, March 27, 2017 – TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ZEJULA (niraparib), an oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian …
Read More· Tesaro joins PARP parade with US approval of Zejula. Unlike its rivals Zejula doesn''t require a BRCA mutation in patients before use. Tesaro''s niraparib has become the third PARP inhibitor to be approved for marketing, with the FDA giving the nod for the drug as a therapy for women with epithelial ovarian, fallopian tube or primary peritoneal ...
Read More· Its lead marketed drug is a poly ADP ribose polymerase (PARP) inhibitor called Zejula (niraparib) indicated for the treatment of ovarian cancer. Zejula holds approvals in the US and Europe for recurrent ovarian cancer in adults who have responded to platinum-based chemotherapy, irrespective of their BRCA mutation and biomarker status.
Read MoreTesaro''s major product is Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit in patients with and without germline mutations in a BRCA gene (gBRCA).
Read More· GlaxoSmithKline detailed the potential market opportunity it sees for Tesaro''s marketed PARP inhibitor Zejula (niraparib) in ovarian cancer during an investor presentation today. GlaxoSmithKline ...
Read More· GSK Makes $5.1 Billion Bet on Tesaro Oncology and Its PARP Inhibitor Zejula. Published: Dec 03, 2018 By Alex Keown. Shares of Tesaro Oncology shot up more than 60 percent in premarket trading after pharma giant GlaxoSmithKline announced it will acquire the Waltham, Mass.-based company for $5.1 billion. For GSK, the deal marks an increased focus ...
Read More· Tesaro''s PARP inhibitor Zejula combined with Merck''s immuno-oncology drug Keytruda failed to impress some analysts in an ovarian cancer study. More News U.S. economic optimism saw a big bounce in ...
Read More· Tesaro earns CHMP thumbs-up for Zejula as three-way PARP race heats up. Zejula is on track to be the first once-daily PARP inhibitor approved in Europe to treat ovarian cancer patients, regardless ...
Read More· Niraparib, first marketed in the U.S. in April under the brand name ZEJULA, has quickly become the most frequently prescribed PARP inhibitor in the U.S. Under the terms of this agreement, TESARO will receive a $100 million upfront payment and is eligible to receive additional milestone payments of up to $240 million related to the achievement of certain …
Read More· Zai Lab in-licensed rights to ZEJULA from Tesaro for China, Hong Kong and Macau as an important, new treatment option for more than 50,000 Chinese patients who suffer from ovarian cancer every year. ZEJULA is a potential best-in-class PARP inhibitor due to its differentiated efficacy, once-daily dosing and superior pharmacokinetic properties including its …
Read MoreGlobally, GSK acquired Zejula in January 2019, through the acquisition of Tesaro, an oncology-focused biopharmaceutical company. This acquisition significantly strengthened and accelerated GSK''s oncology pipeline, bringing extended scientific capabilities and expertise.
Read More· Tesaro, a biopharmaceutical (oncology-focused) company, is involved in manufacturing and marketing ovarian cancer drugs such as Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor and others, that aid in treating ovarian cancer.
Read MoreZejula is now the only, once-daily PARP inhibitor approved as monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation in both the recurrent maintenance and late-line treatment settings
Read More"The introductions of ZEJULA in Germany and the UK are significant milestones for TESARO as we bring transformative therapies to patients with cancer around the globe. With two approved products in Europe, we are working quickly to make our medicines available in the 17 European countries where we have a direct presence."
Read More· TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.
Read More· Niraparib, first marketed in the U.S. in April under the brand name ZEJULA, has quickly become the most frequently prescribed PARP inhibitor in the U.S. Under the terms of this agreement, TESARO will receive a $100 million upfront payment and is eligible to receive additional milestone payments of up to $240 million related to the achievement of certain …
Read MoreCopyright © . AMC CRUSHER All rights reserved. Sitemap
